Trial Profile
An Open Label Phase II, Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 04 Oct 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 04 Oct 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 05 Apr 2022 Planned End Date changed from 1 Sep 2021 to 1 Dec 2023.